| scholarly article | Q13442814 |
| P50 | author | Susan L. Cohn | Q41883268 |
| P2093 | author name string | Michael L Maitland | |
| Yufeng Tian | |||
| Alexandre Chlenski | |||
| Helen R Salwen | |||
| Qiwei Yang | |||
| Lisa J Guerrero | |||
| Nisha C Kakodkar | |||
| Radhika R Peddinti | |||
| P2860 | cites work | Neuroblastoma: biology, prognosis, and treatment | Q37683919 |
| Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma | Q40169611 | ||
| Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models | Q40198053 | ||
| Proteomic analysis of neuroblastoma subtypes in response to mitogen-activated protein kinase inhibition: profiling multiple targets of cancer kinase signaling | Q40285212 | ||
| Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors | Q43140228 | ||
| Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-a | Q43272233 | ||
| Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. | Q45113187 | ||
| Neuroblastoma | Q54265665 | ||
| Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma | Q57734254 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling | Q28296761 | ||
| Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors | Q33955200 | ||
| Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma | Q34733110 | ||
| VEGF-targeted therapy: mechanisms of anti-tumour activity. | Q34791610 | ||
| The regulation of angiogenesis in neuroblastoma | Q35184933 | ||
| Signal transduction via the MAP kinases: proceed at your own RSK. | Q36381460 | ||
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 | ||
| Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors | Q36807146 | ||
| Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors | Q37104791 | ||
| Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program | Q37295112 | ||
| P433 | issue | 4 | |
| P921 | main subject | neuroblastoma | Q938205 |
| P304 | page(s) | 642-647 | |
| P577 | publication date | 2011-12-06 | |
| P1433 | published in | Pediatric Blood & Cancer | Q15754342 |
| P1476 | title | Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth | |
| P478 | volume | 59 |
| Q35078100 | A mechanism linking Id2-TGFβ crosstalk to reversible adaptive plasticity in neuroblastoma |
| Q26771708 | Cell Proliferation in Neuroblastoma |
| Q38010377 | Development of treatment strategies for advanced neuroblastoma |
| Q50073387 | Emerging and investigational therapies for neuroblastoma. |
| Q38108399 | Emerging drugs for neuroblastoma |
| Q46314776 | Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies |
| Q36916322 | HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells |
| Q36250783 | Molecular profiling of childhood cancer: Biomarkers and novel therapies |
| Q52639269 | Neuroblastoma: clinical and biological approach to risk stratification and treatment. |
| Q42736880 | Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases |
| Q52597787 | Too many targets, not enough patients: rethinking neuroblastoma clinical trials. |
| Q37259264 | Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma |
Search more.